Standard Biotools Stock Analysis
| LAB Stock | USD 1.60 0.02 1.23% |
Standard Biotools is overvalued with Real Value of 0.98 and Target Price of 0.55. The main objective of Standard Biotools stock analysis is to determine its intrinsic value, which is an estimate of what Standard Biotools is worth, separate from its market price. There are two main types of Standard Biotools' stock analysis: fundamental analysis and technical analysis.
The Standard Biotools stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Standard Biotools' ongoing operational relationships across important fundamental and technical indicators.
Standard |
Standard Stock Analysis Notes
About 73.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Standard Biotools has Price/Earnings To Growth (PEG) ratio of 0.31. The entity recorded a loss per share of 0.69. The firm had not issued any dividends in recent years. Standard Biotools had a split on the 6th of December 2001. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people. To find out more about Standard Biotools contact Michael Egholm at 650 266 6000 or learn more at https://www.standardbio.com.Standard Biotools Quarterly Total Revenue |
|
Standard Biotools Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Standard Biotools' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Standard Biotools or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools may become a speculative penny stock | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 106.34 M. Reported Net Loss for the year was (74.66 M) with loss before taxes, overhead, and interest of (1.45 M). | |
| Standard Biotools has about 81.31 M in cash with (43.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Standard Biotools has a poor financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Flow Cytometry Market Expected To Reach USD 11553.44 Mn by 2032, Growing at 8.21 percent CAGR Introspective Market Research |
Standard Biotools Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Standard Biotools previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Standard Largest EPS Surprises
Earnings surprises can significantly impact Standard Biotools' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-10-30 | 2024-09-30 | -0.09 | -0.07 | 0.02 | 22 | ||
2013-02-12 | 2012-12-31 | -0.16 | -0.14 | 0.02 | 12 | ||
2019-05-02 | 2019-03-31 | -0.25 | -0.28 | -0.03 | 12 |
Standard Biotools Thematic Classifications
In addition to having Standard Biotools stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | Measuring and Control EquipmentUSA Equities from Measuring and Control Equipment industry as classified by Fama & French |
Standard Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 595.61 M.Standard Profitablity
The company has Net Profit Margin of (0.8) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.29) %, which entails that for every $100 of revenue, it lost $0.29.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.36) | (0.38) | |
| Return On Assets | (0.23) | (0.24) | |
| Return On Equity | (0.46) | (0.48) |
Management Efficiency
Standard Biotools has Return on Asset of (0.1469) % which means that on every $100 spent on assets, it lost $0.1469. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3725) %, meaning that it generated no profit with money invested by stockholders. Standard Biotools' management efficiency ratios could be used to measure how well Standard Biotools manages its routine affairs as well as how well it operates its assets and liabilities. As of November 24, 2024, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Standard Biotools' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 3.4 M, whereas Total Assets are forecasted to decline to about 228.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.06 | 2.16 | |
| Tangible Book Value Per Share | 0.70 | 0.74 | |
| Enterprise Value Over EBITDA | (4.07) | (4.27) | |
| Price Book Value Ratio | 1.07 | 2.08 | |
| Enterprise Value Multiple | (4.07) | (4.27) | |
| Price Fair Value | 1.07 | 2.08 | |
| Enterprise Value | 376.6 M | 274.1 M |
Evaluating the management effectiveness of Standard Biotools allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Standard Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Operating Margin (0.29) | Profit Margin (0.80) | Beta 1.569 | Return On Assets (0.15) | Return On Equity (0.37) |
Technical Drivers
As of the 24th of November, Standard Biotools has the Coefficient Of Variation of (1,925), risk adjusted performance of (0.03), and Variance of 17.08. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Standard Biotools, as well as the relationship between them.Standard Biotools Price Movement Analysis
The output start index for this execution was two with a total number of output elements of fifty-nine. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Standard Biotools middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Standard Biotools. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Standard Biotools Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Standard Biotools insiders, such as employees or executives, is commonly permitted as long as it does not rely on Standard Biotools' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Standard Biotools insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Standard Biotools Outstanding Bonds
Standard Biotools issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Standard Biotools uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Standard bonds can be classified according to their maturity, which is the date when Standard Biotools has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Standard Biotools Predictive Daily Indicators
Standard Biotools intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Standard Biotools stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Standard Biotools Forecast Models
Standard Biotools' time-series forecasting models are one of many Standard Biotools' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Standard Biotools' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Standard Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Standard Biotools prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Standard shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Standard Biotools. By using and applying Standard Stock analysis, traders can create a robust methodology for identifying Standard entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.70) | (0.73) | |
| Operating Profit Margin | (0.72) | (0.76) | |
| Net Loss | (0.70) | (0.74) | |
| Gross Profit Margin | 0.47 | 0.63 |
Current Standard Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Standard analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Standard analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 0.55 | Strong Buy | 3 | Odds |
Most Standard analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Standard stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Standard Biotools, talking to its executives and customers, or listening to Standard conference calls.
Standard Stock Analysis Indicators
Standard Biotools stock analysis indicators help investors evaluate how Standard Biotools stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Standard Biotools shares will generate the highest return on investment. By understating and applying Standard Biotools stock analysis, traders can identify Standard Biotools position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 82.3 M | |
| Long Term Debt | 4 M | |
| Common Stock Shares Outstanding | 79.2 M | |
| Total Stockholder Equity | 163.2 M | |
| Tax Provision | 684 K | |
| Property Plant And Equipment Net | 54.9 M | |
| Cash And Short Term Investments | 114.9 M | |
| Cash | 51.7 M | |
| Accounts Payable | 9.2 M | |
| Net Debt | 46.5 M | |
| 50 Day M A | 1.8738 | |
| Total Current Liabilities | 109.3 M | |
| Other Operating Expenses | 169.4 M | |
| Non Current Assets Total | 164.9 M | |
| Non Currrent Assets Other | 2.3 M | |
| Stock Based Compensation | 13.1 M |
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |